Compare Stocks: VTVT, BIOA, AQST, and OVID

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.29 +8.9%	$4.12	$2.93 ▼ $7.55	$494.34M	1.49	1.95 million shs	7.28 million shs
BIOA BioAge Labs	$11.45 -2.3%	$19.93	$4.25 ▼ $25.95	$525.52M	0.94	1.36 million shs	592,287 shs
OVID Ovid Therapeutics	$2.62 -0.4%	$2.45	$0.52 ▼ $3.11	$490.86M	0.21	1.50 million shs	1.25 million shs
VTVT vTv Therapeutics	$34.29 -3.1%	$33.40	$14.00 ▼ $44.00	$139.32M	0.29	110,252 shs	97,697 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+8.88%	+13.19%	+4.13%	+3.13%	+10.00%
BIOA BioAge Labs	-2.30%	+6.22%	-52.96%	-37.05%	+164.43%
OVID Ovid Therapeutics	-0.38%	+12.45%	+3.97%	-8.71%	+408.84%
VTVT vTv Therapeutics	-3.05%	+5.87%	+2.39%	+6.79%	+143.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.29 +8.9%	$4.12	$2.93 ▼ $7.55	$494.34M	1.49	1.95 million shs	7.28 million shs
BIOA BioAge Labs	$11.45 -2.3%	$19.93	$4.25 ▼ $25.95	$525.52M	0.94	1.36 million shs	592,287 shs
OVID Ovid Therapeutics	$2.62 -0.4%	$2.45	$0.52 ▼ $3.11	$490.86M	0.21	1.50 million shs	1.25 million shs
VTVT vTv Therapeutics	$34.29 -3.1%	$33.40	$14.00 ▼ $44.00	$139.32M	0.29	110,252 shs	97,697 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+8.88%	+13.19%	+4.13%	+3.13%	+10.00%
BIOA BioAge Labs	-2.30%	+6.22%	-52.96%	-37.05%	+164.43%
OVID Ovid Therapeutics	-0.38%	+12.45%	+3.97%	-8.71%	+408.84%
VTVT vTv Therapeutics	-3.05%	+5.87%	+2.39%	+6.79%	+143.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$8.50	98.14% Upside
BIOA BioAge Labs	2.71	Moderate Buy	$36.57	219.40% Upside
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.71	118.10% Upside
VTVT vTv Therapeutics	2.63	Moderate Buy	$55.83	62.83% Upside

Current Analyst Ratings Breakdown

Latest VTVT, BIOA, AQST, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $42.00
8/3/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00
7/31/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
7/31/2026	BIOA BioAge Labs	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
7/31/2026	BIOA BioAge Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $35.00
7/21/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/21/2026	OVID Ovid Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	AQST Aquestive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	VTVT vTv Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $57.00

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$44.54M	12.09	N/A	N/A	($0.28) per share	-15.32
BIOA BioAge Labs	$8.99M	58.46	N/A	N/A	$7.59 per share	1.51
OVID Ovid Therapeutics	$7.25M	67.45	N/A	N/A	$1.00 per share	2.62
VTVT vTv Therapeutics	$1.02M	132.45	N/A	N/A	$16.36 per share	2.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.61	N/A	N/A	N/A	-137.08%	N/A	-49.33%	8/11/2026 (Estimated)
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
OVID Ovid Therapeutics	-$17.41M	-$0.29	N/A	N/A	N/A	-240.11%	-22.51%	-18.67%	8/12/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	8/11/2026 (Estimated)

Latest VTVT, BIOA, AQST, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	OVID Ovid Therapeutics	-$0.10	N/A	N/A	N/A	$0.02 million	N/A
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	N/A	N/A	N/A	$11.42 million	N/A
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million
5/13/2026	Q1 2026	AQST Aquestive Therapeutics	-$0.14	-$0.07	+$0.07	-$0.07	$10.90 million	$14.45 million
5/13/2026	Q1 2026	VTVT vTv Therapeutics	$0.21	$1.65	+$1.44	$1.65	$20.00 million	$36.84 million
5/12/2026	Q1 2026	OVID Ovid Therapeutics	-$0.12	-$0.12	N/A	-$0.12	$0.06 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.10	3.85
BIOA BioAge Labs	N/A	17.19	17.19
OVID Ovid Therapeutics	0.06	10.17	10.17
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
BIOA BioAge Labs	N/A
OVID Ovid Therapeutics	72.24%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
BIOA BioAge Labs	17.55%
OVID Ovid Therapeutics	7.00%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	125.47 million	116.92 million	Optionable
BIOA BioAge Labs	N/A	45.90 million	37.84 million	N/A
OVID Ovid Therapeutics	60	186.64 million	173.58 million	Optionable
VTVT vTv Therapeutics	9	3.94 million	3.70 million	Not Optionable

VTVT, BIOA, AQST, and OVID Headlines

Recent News About These Companies

HC Wainwright Predicts Weaker Earnings for vTv Therapeutics

August 10 at 1:12 AM | americanbankingnews.com

HC Wainwright Lowers Earnings Estimates for vTv Therapeutics

August 10 at 1:11 AM | marketbeat.com

HC Wainwright Cuts vTv Therapeutics (NASDAQ:VTVT) Price Target to $42.00

August 9 at 3:51 AM | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Downgraded by Wall Street Zen to Sell

August 8 at 1:13 AM | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen

August 8 at 1:11 AM | marketbeat.com

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | markets.businessinsider.com

vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS

August 6, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright

August 6, 2026 | marketbeat.com

vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving Average - Here's What Happened

August 1, 2026 | marketbeat.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts

July 24, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving Average - Here's Why

July 24, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says

July 16, 2026 | marketbeat.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, BIOA, AQST, and OVID Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.29 +0.35 (+8.88%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$4.43 +0.14 (+3.24%)

As of 08:23 AM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

BioAge Labs NASDAQ:BIOA

$11.45 -0.27 (-2.30%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$11.42 -0.02 (-0.22%)

As of 08:19 AM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Ovid Therapeutics NASDAQ:OVID

$2.62 -0.01 (-0.38%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$2.62 +0.00 (+0.04%)

As of 07:06 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

vTv Therapeutics NASDAQ:VTVT

$34.29 -1.08 (-3.05%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$34.30 +0.01 (+0.03%)

As of 07:00 AM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, BIOA, AQST, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, BIOA, AQST, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, BIOA, AQST, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, BIOA, AQST, and OVID Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

BioAge Labs NASDAQ:BIOA

Ovid Therapeutics NASDAQ:OVID

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, BIOA, AQST, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, BIOA, AQST, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, BIOA, AQST, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, BIOA, AQST, and OVID Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

BioAge Labs NASDAQ:BIOA

Ovid Therapeutics NASDAQ:OVID

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools